HopeStage
Back to all studies
CompletedNCT03943537

Intranasal Insulin and Brain Energy Use in Psychosis

About this titleRead the official source — NCT03943537
Medication studyAges 18–40United StatesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 40 years.

Listed locations
BelmontSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: October 1, 2019
Recruitment status
Completed
Enrollment listed in the registry
87
Sponsor
Mclean Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 40 Years
Official registry ID
NCT03943537
Official title
Show the full official title

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Belmont

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Mclean Hospital, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including Intranasal Insulin.

Who was this study for?

Listed age limits: 18 years to 40 years.

Want to explore more studies?

Explore studies